Lilly (Eli)
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and incorporated in Indiana in 1901. The company discovers, develops, manufactures, and markets human pharmaceutical products worldwide, with operations spanning the United States, including Puerto Rico, Europe, and Asia. Products are… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lilly (Eli) does
In the company’s own words
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and incorporated in Indiana in 1901. The company discovers, develops, manufactures, and markets human pharmaceutical products worldwide, with operations spanning the United States, including Puerto Rico, Europe, and Asia. Products are sold in approximately 90 countries.
The company operates as a single business segment focused on innovative medicines across four primary therapeutic areas: Cardiometabolic Health, Oncology, Immunology, and Neuroscience. Major cardiometabolic products include Mounjaro and Zepbound for diabetes and obesity treatment, Trulicity for type 2 diabetes, Jardiance for diabetes and heart failure, and various insulin formulations. The oncology portfolio includes Cyramza, Erbitux, Verzenio, Jaypirca, Retevmo, and Inluriya. Immunology offerings comprise Olumiant, Omvoh, Taltz, and Ebglyss. Neuroscience products include Emgality for migraine prevention and Kisunla for Alzheimer's disease.
Lilly's distribution strategy combines traditional wholesale channels with innovative direct-to-patient approaches through LillyDirect, its digital health platform. In the United States, three major wholesale distributors—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each account for significant portions of consolidated revenue. The company maintains its own sales organizations in many countries while utilizing third-party distribution arrangements in others.
The company's competitive positioning relies on intellectual property protection, including compound patents, data exclusivity, and trademark portfolios. Key products maintain patent protection through the 2020s and 2030s, with certain products benefiting from pediatric or orphan drug exclusivity extensions. Lilly faces competition from generic pharmaceuticals, biosimilars, and counterfeit products, particularly in the growing obesity medicine market where reimbursement barriers significantly impact sales volumes.
The company website is www.lilly.com. Lilly's long-term strategy centers on discovering and developing innovative, cost-effective products that deliver improved patient outcomes while maintaining operational efficiency in a highly competitive global pharmaceutical environment.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- INDIANAPOLIS, IN
- Fiscal year end
- December
- CIK
- 59478
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lilly (Eli) — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Lilly (Eli) · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Lilly (Eli)’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Lilly (Eli)’s bonds, as funds hold them
Funds report holding 54 issues of Lilly (Eli)’s debt, $5.20B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.67%, maturing 2026 to 2066.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lilly (Eli) and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lilly (Eli)'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lilly (Eli)'s last four quarterly filings that the numbers alone won't show?”